Tifacogin (Chiron Corp/Pharmacia Corp).

Area of Science:

• Biotechnology and Pharmaceutical Development
• Infectious Diseases and Immunology
• Vascular Biology

Background:

• Tifacogin is a recombinant tissue factor pathway inhibitor (rTFPI) developed as a potential sepsis therapeutic.
• Development is a collaboration between Pharmacia Corp (formerly GD Searle) and Chiron.
• The drug has advanced to Phase III clinical trials.

Purpose of the Study:

• To summarize the development and patent landscape of Tifacogin (rTFPI) for sepsis treatment.
• To highlight key research collaborations and intellectual property surrounding TFPI.
• To provide an overview of the drug's developmental status and market potential.

Main Methods:

• Review of patents related to TFPI and its therapeutic applications.
• Analysis of research and development agreements between Pharmacia (Searle) and Chiron.
• Tracking of clinical trial progress and regulatory milestones.
• Examination of financial analyst predictions regarding market potential.

Main Results:

• Tifacogin (rTFPI) is in Phase III trials, with anticipated regulatory filings in 2002.
• Multiple patents cover TFPI expression methods (yeast vs. E. coli) and its use in treating sepsis, microvascular thrombosis, and reperfusion injury.
• A collaboration between Searle and Chiron, originating from independent research, governs the compound's development, manufacturing, and marketing.
• Financial analysts projected a 50% market probability and significant peak sales potential.

Conclusions:

• Tifacogin represents a significant development in sepsis treatment, with a complex patent and collaboration history.
• The drug's progression through Phase III trials indicates its potential as a novel therapeutic.
• Intellectual property and strategic partnerships are crucial in the advancement of rTFPI for clinical use.